



President Annual Activity Report for 2020

Nicolaus Kröger, EBMT President

Science

COVID-19

In terms of activity, 2020 was severely affected by the COVID-19 pandemic but despite the challenges, EBMT was able to demonstrate a strong commitment to its patients and members by providing:

- **guidelines** for transplant units, recipients, and donors of hematopoietic cells. These guidelines have been updated each time new information was obtained about COVID-19 epidemiology and clinical outcome.
- COVID-19 **vaccines information** produced by the IDWP– also available on the EBMT website.
- 9 COVID-focus **webinars** for physicians and nurses, organised with other sister societies

<https://www.ebmt.org/covid-19-and-bmt>

The Registry


New Registrations for Cellular Therapy in 2020

EBMT has actively encouraged centres to report on all cases involved in the treatment of patients using a CAR-T product whether commercial or investigational.

All centres should continue to complete the current Cell Therapy Form outlined in ProMiSe on a timely basis to create an accurate patient representation.

The graph below illustrates the steady growth of new reported cases into the EBMT Registry during 2020 and the reflected number of centres.

Number of CAR-T cell treated patients registered in the EBMT Registry



Source: EBMT Registry, December 2020

The map below represents a geographical approach in blue of all our reporting countries who are continually submitting data to the EBMT Registry.


Countries reporting CAR-T cell treated patients to the EBMT Registry



Source: EBMT Registry, December 2020

The Registry - Registry Upgrade Project

The Registry upgrade project has faced several challenges during the course of 2020, and these caused a complete halt of the data migration mid-year. Due to the high priority of this project, a thorough analysis on behalf of the EBMT was carried out. Looking at several technical as well as functional issues, this has resulted in a **comprehensive Test plan** created by the vendor. Together with the vendor, an approach was defined in order to **address all the identified issues, find solutions and build towards a strong foundation to continue the project as a whole.**



Outcomes of these tests are expected in the Q1 of 2021, whereafter new Validation and Test plans will be developed by the Registry in order to complete the data migration.

The Registry - Resource

In 2020 the Registry has transitioned from the previous Head, Debra Gordon, to the new Registry Director, Bas Middelkoop, who joined the EBMT Registry in December 2020.

Due to the loss of two members of staff in 2020 the Registry has been looking to replace the two vacancies and succeeded. Two experienced Data Analysts have joined the Registry IT department in Q1 of 2021. Also the Registry is looking to expand the team further in 2021, giving the Registry team more hands and expertise to face the challenges for the coming year.

Collaboration with Kite

In June 2020, the EBMT announced a new collaboration with Kite, a Gilead Company, to study the long-term outcomes of patients treated with Yescarta® (axicabtagene ciloleucel), a CAR T cell therapy.

Under the terms of the collaboration, EBMT will collect treatment and long-term safety and efficacy data for 20 years from patients treated with Yescarta® in the EBMT registry for cellular therapy.


Education

46th Annual Meeting [Virtual]

On March 4th 2020, EBMT decided to postpone the Meeting until the end of August.

On April 2nd, reported global COVID-19 infections reached one million.

On May 6th, EBMT announced that it's Annual Meeting would be going fully virtual for the first time, ever.



Despite the ongoing pandemic, the objective of EBMT with regards to education remained unchanged – to **share leading cutting-edge science** and to **provide the highest quality of education** in the field of stem cell transplantation and cellular therapy.

VIRTUAL
46th Annual Meeting of the EBMT
29 August - 1 September 2020

Attendance:

6,783
registered
attendees



89
countries

Programme:



1,315
submitted abstracts



Invited Faculty
235



Sessions
95



Presentations
269



Awards granted
26

Other educational events

LOCATION	DATES	Nº PARTICIPANTS	WORKING PARTIES	TITLE
Leipzig, Germany	24-25 January 2020	51	CMWP	Chronic Malignancies Working Party Meeting
Sitges (Barcelona), Spain	30 Jan - 1 February 2020	1000 / Livestreaming: 189	EBMT - EHA	2nd European CAR T Cell Meeting
Virtual	8-10 July 2020	377	PDWP, SAAWP, IEWP, NG	Midterm Focus Meeting on Non-Malignant Diseases
Virtual	29 Aug - 1 Sep 2020	6,783	EBMT	46th Annual Meeting of the European Society for Blood and Marrow Transplantation
Virtual	24-25 September 2020	217	ADWP	Autoimmune Diseases Working Party Meeting
Virtual	25 September 2020	74	IEWP	Inborn Errors Working Party Business Meeting
Virtual	8-9 October 2020	134	NG	12th Nurses International Study Day & 4th Nurses Research Study Day Meetings
Virtual	10 October 2020	37	CMWP	Chronic Malignancies Working Party Meeting
Virtual	28-30 October 2020	124	IDWP	23rd Infectious Diseases Working Party Meeting
Virtual	4-6 November 2020	373* platform opened until Feb 2	EBMT	5th International Transplant Course

E-learning

Another important development in EBMt Education in 2020 was the launch of the **e-learning platform**.


- The e-learning taskforce laid out the strategy for the advancement of online education.
- The e-learning unit provided with COVID-19 webinars in April/May, followed by an increased demand for all types of online learning.
- Now all EBMt Members have access to a multitude of resources which are available for free, such as webinars, e-courses, forums, exams and more.

Advocacy & Quality of Care

GoCART Coalition

- In November 2020, the EBMT and EHA announced a strategic partnership to empower Europe to become a global leader in the cellular therapy field for haematological diseases.
- The two societies join forces and bring their collective resources and expertise to the newly founded GoCART coalition.

JACIE – Standards and Accreditation in 2020



JACIE's 2020 activity was severely affected by the pandemic from mid-March. **40 applications** were received, **18 inspections** were completed before on-site inspections were cancelled and **47 accreditations** were awarded.

JACIE is developing a **remote inspection process** to be launched in the first quarter of 2021.

JACIE - Other

Benchmarking

The FACT-JACIE Standards require centres to review their clinical outcomes against wider datasets, referred to as benchmarking. EBMT as a registry holder is in a unique position to offer an international benchmarking scheme to centres that report data.

In October 2020, the first phase of this service was launched whereby reports of data-completeness were provided to 416 qualifying centres for the period 2013-2016. The second phase in February 2021 will see the provision of clinical outcome benchmarking reports to those centres that have met the data completeness threshold.

Benchmarking will thereafter become an annual exercise. The next edition will be in June 2021 based on 2015-2019 data.

8th Edition of FACT-JACIE Standards

The process to prepare the 8th edition of the FACT-JACIE Standards continued throughout 2020. The first draft was opened for public consultation in April 2020 for 3 months. 770 comments from 78 participants in 12 countries were received and that feedback was reviewed by the Standards sub-committees during the last quarter of 2020 before the final draft will be presented to the FACT and EBMT Boards for approval in early 2021.

The definitive text will be published in May 2021.

The Nurses Group activities 2020

Working Party Nurses:

This role is now firmly established as a valuable resource in each of the medical working parties. The goal to develop collaborative nursing/medical projects for patient benefit continues to develop at pace. The roles have begun to adapt to the needs of the WP with many nurses taking more responsibility for education. There have been 2 papers published by the PDWP with nursing input this year. There is currently 1 nurse vacancy in the inborn errors WP.

4 Publications

2 Oral presentations

6 Educational events

Nursing Education:

- **COVID-19 webinars** for nurses (Palliative Care guidance for patients with severe COVID-19; Psychological impact of COVID-19 pandemic on nurses: experiences and tips)
- **Preparation of the E-textbook for nurses:** it will be available on the e-learning platform.

Other key achievements

- Reinforcement of the **collaborative relationship with our sister societies** - CIBMTR, ASTCT and APBMT - with respect to data collection harmonisation and scientific exchange.
- Opening of an **EBMT Office in Shanghai** (China) with the objective to promote convenient and in-depth exchange between the Chinese haematology community and the EBMT, strengthen multi-centre clinical innovation and cooperation, share scientific experience, standards and protocols, and ultimately provide the best treatment and care for patients.
- Presentation of the EBMT **new logo and name** as well as the refocused **mission, vision and core values**—which better represent worldwide involvement and modernity.

Other key achievements

- Creation of the so-called **'Equality, Diversity and Inclusion' (EDI) working group** to address our society's gender imbalance at senior levels as well as to promote broader equality, diversity and inclusion issues, and ultimately aiming to improve the inclusion of people across gender, ethnicity, geography, and social categories.
- Release of the **Patient Engagement Survey**, on behalf the EBMT Patient Engagement Taskforce, to understand the current point of view of all EBMT stakeholders (i.e. health care providers, industry staff, government officials, patients, donors and caregivers) regarding the engagement of patients in HCT and cell therapy data-collection and research.
- Launch of the **EBMT Trainee Committee** with the overall aim of addressing the specific needs of trainees working in BMT and cellular therapy, as well as providing advice and support for trainees at all levels.


2020 elections and revised organigram

John Snowden (Sheffield, UK), Secretary

Raffaella Greco (Milan, Italy), ADWP Chair

Rafael de la Cámara (Madrid, Spain), IDWP Chair

Bertram Glass (Berlin, Germany), LWP Chair



From left to right: J. Snowden; R. Greco; R. de la Cámara; B. Glass

- Medical Officer: Isabel Sánchez-Ortega
- EBMT restructuring in 5 departments:
 1. Support
 2. Sales
 3. Registry
 4. Clinical Research
 5. Education & Events



14-17
March
2021

virtual
47th Annual Meeting
of the EBMT

Thanks!





Treasurer's Annual Financial Report for 2020

Harry Dolstra, EBMT Treasurer

Final 2020 numbers for voting

Financial highlights

Source of Income

	2020	
	EUR	%
EBMT Members donations	650,000	6.2%
Scientific Sponsors donations	475,000	4.5%
Annual Meeting	4,735,000	45.0%
Results from investments	35,000	0.3%
Grants for Studies, Clinical Trials & Education	4,381,000	41.7%
Accreditation (JACIE)	241,000	2.3%
Total Income	10,517,000	100.0%

Destination of resources

	2020	
	EUR	%
Scientific Studies	2,294,000	27.9%
EBMT Registry	731,000	8.9%
Annual Meeting	1,349,000	16.3%
Educational Activities	1,787,000	21.6%
Standards & Accreditation (JACIE)	512,000	6.2%
Management and Administration	1,586,000	19.2%
Total Expenditure	8,259,000	100.0%

Position of EBMT - rating

Program %	Cost to Raise \$100	Efficiency Rating
90-100%	\$0 - 4	A+
80 - 89%	\$5 - 11	A
75 - 79%	\$12 - 15	A-
72 - 74%	\$16 - 19	B+
68 - 71%	\$20 - 26	B
65 - 67%	\$27 - 30	B-
61 - 64%	\$31 - 33	C+
56 - 60%	\$34 - 37	C
50 - 55%	\$38 - 40	C-
36 - 49%	\$41 - 59	D
0 - 35%	\$60 - 100	F

Current position EBMT

Final 2020 numbers for voting

Financial outcome	2020	
	EUR	%
Total Income	10,517,000	100.0%
Total Costs	8,259,000	78.5%
Gross Result	2,258,000	21.5%
Earmarked	- 80,000	-0.8%
Net result	2,338,000	22.3%

Final Conclusions

The continued positive financial development of the organization has allowed EBMT to further building on strategic goals and improve its structure.

Currents highlights: e-learning, registry upgrade, cellular therapy registry, benchmarking system, CART PASS studies.

A total of € 500K will be earmarked in line with the board decisions for structural innovation (€ 300K) and registry implementation (€ 200K).

A total of € 580K from earmarked reserves is used for running projects.

The residual budget of € 2,338K will be returned to our reserves and used to further secure our key staff positions and main strategic projects in case of any unforeseen financial serious adverse event.

In 2021 we plan to use a total of € 1.086 K earmarked reserves in line with the Board's decisions for registry implementation (€ 775 K) and structural innovation (€ 311 K).






Continue with the well-balanced strategic financial roadmap

In 2020, the main challenge was to secure all Staff positions while further optimizing EBMT organizations through a well-balanced financial COVID-19 contingency plan and roadmap for the future in order to be able to cover all financial challenges in line with our ambitions but also further strengthen a strong backbone.

The EBMT Board decided to partially release allocated reserves in 2020 (580 k€) to support our roadmap and EBMT organization for the next few years on its strategic topics and areas.

Income and human resources development



Spending our financial resources on our missions

Our annual income has been used to further work on our mission and improve the organizational structure of EBMT in order to strengthen our growing organization for achieving our mission goals.

The budget needed for management (i.e., board and executive office expenses) increased to 19,2% which is resulting in allocating 80,8% to our scientific studies, Registry, accreditation and education including the Annual Meeting, E-learning and Educational events .

Therefore, EBMT remains a very efficient organization when assessed by international rankings (A in line with CharityWatch, 2019: A+).



AUDITING PROCESS



At the time of preparation this presentation (1 March 2021), the audit process had not yet been completed.

No information from the auditors has reached us that indicates we won't obtain an "unqualified opinion".

It will be the sixth consecutive time EBMT obtains an unqualified opinion. This demonstrates that the EBMT is maintaining its high standard of modern management, improving its financial stability and provides assurance that money is spent and allocated according to our mission.

At the end of the audit process EBMT will receive an Auditor's Management Letter. The outcome of this will be presented in the Board meeting after obtaining the letter.



THANKS TO:


Financial team, EBMT offices



Liesbeth
Hoekstra



Bas Natkiel



Erwin Timmers



Rugène Rogers

Financial committee members from 2019 and update ToR 4 year mandate



Harry Schouten



Alejandro Madrigal



Financial options for future strategic goals in and beyond 2021

Continuance of development of the registry

Implementing benchmarking

Extend the cellular therapy project and PASS studies

Investing in IT and human resources

Extend e-Learning content

Risk management: EBMT's liquidity

Current ratio (liquidity of an organization):

This indicator says something about the financial position of the organization. It shows if current liabilities can be covered by the current assets. A ratio between 1.2 - 1.5 is considered healthy.

Current ratio is calculated as follows: current assets / current liabilities

$$\text{Current ratio} = \frac{22,738,000}{10,364,000} = 2.2$$

Cash runway (how long can the organization run without income):

Cash runway ratio is calculated as follows: current assets / current + future liabilities

Burn: approximately 1,5 Mio Euro a month

$$\text{Runway ratio} = 12 \times \frac{22,738,000}{18,185,000} = 15$$

Thanks!



A world map is visible in the background, rendered in a dark purple color. Overlaid on the map is a network of red lines and dots, representing global connectivity. The dots are of varying sizes and are connected by thin red lines, creating a web-like pattern across the continents.


EBMT Secretary's Annual Activity & Membership Report for 2020

47th Annual Meeting of the EBMT– Virtual

John Snowden, EBMT Secretary

Membership Overview

Global Figures



CENTRES Membership Overview

Global Figures

	GAM 2021	GAM 2020
<i>Number of EBMT CENTRES</i>	570	574
<i>Of which PROVISIONAL centres</i>	9	15
<i>Of which have been REACTIVATED</i>	4	3
<i>Of which FULL centres reporting</i>	512	505
<i>Of which ASSOCIATE centres</i>	58	54

Source: Promise January 2021

CENTRES Membership Overview

Per country

Position	Country	Number of centres GAM 2021	Number of centres GAM 2020
1	Germany	89	86
2	Italy	79	80
3	UK	51	52
4	France	48	51
5	Spain	47	46
6	Turkey	39	40
7	Poland	17	20
8	Belgium	15	15
9	The Netherlands	15	13
10	Switzerland	12	12

The **570** EBMT centres are located in **71** countries

The **top 10** split of Centres represents **412** Centres (72% of total)

Source: Promise January 2021

CENTRES Membership New EBMT members

The following 9 Provisional Centre Members await your approval.

CIC	Institution	City	Country
894	Hospital Italiano de Buenos Aires	Buenos Aires	Argentina
896	ICO H.U. de TARRAGONA JOAN XXIII	Tarragona	Spain
898	Mount Elizabeth Hospital	Singapore	Singapore
986	CENTRE FOR CLINICAL HAEMATOLOGY	Singapore	Singapore
1000	Rosales Ortiz	Buenos Aires	Argentina
1001	Bahrain Oncology Center	Bahrain	Bahrain
1002	FUNDALEU	Buenos Aires	Argentina
1003	Meyer University Children Hospital	Firenze	Italy
1004	Afyonkarahisar Health Sciences University	Afyonkarahisar	Turkey

CENTRES Membership Overview

Centers Membership Status Changes

The following number of member centers have had their membership status changed due to data reporting:

- **Full to Associate: 5**

5 Centers have stopped reporting and have been moved from Full members to ASSOCIATE

- **Associate to Full: 1**

1 Centre has resumed reporting and has been moved from Associate to FULL

INDIVIDUAL Membership Overview

Global Figures

	GAM 2021	GAM 2020
Number of INDIVIDUAL members	204	144
<i>Of which PROVISIONAL individuals</i>	26	26
<i>Physicians</i>	119	100
<i>Nurses</i>	45	38
<i>Other</i>	0	3
<i>Patient Representative</i>	0	2
Honorary members	32	30

Source: Promise January 2020

INDIVIDUAL Membership Overview - New EBMT members

The following 26 Provisional Individual Members await your approval.

CIC	Name	Role	Country
10256	Marta Paulina Trojniak	Pharmacist	Italy
10257	Silvana Novelli	Physician	Spain
10259	Elisa Sala	Physician	Germany
10260	Stalin Ramprakash	Physician	India
10261	Nihar Desai	Student	India
10262	Priyanka Chauhan	Student	India
10263	Mia Furebring	Physician	Sweden
10328	Piyush Vyas	Physician	Poland
10329	Pedro Henrique de Lima	Physician	France
10330	Fiona Roberts	Physician	UK
10331	Vimal Kumar Gunaseka	Physician	India
10332	Teija Schroeder	Nurse	Finland
10334	Venkata Sreekanth Sampath	Physician	Singapore

CIC	Name	Role	Country
10335	Mauricio Sarmiento	Physician	Chile
10336	Bella Maldonado	Physician	Ecuador
10337	Theresa Cole	Physician	Australia
10340	Miguel Ángel Hernández Martinez	Scientist	Cuba
10341	Oscar Peña	Physician	Colombia
10346	Joycelyn Sim	Physician	China
10347	Arnaud Petit	Physician	France
10348	Yasmina Serroukh	Physician	Canada
10349	Lars Klingen Gjaerde	Student	Denmark
10420	Laurent Garderet	Physician	France
10874	Angela Moreschi Woods	Nurse	USA
10875	Sasidaran Kandasam	Physician	India
10876	Aruna Rajendran	Physician	India

2021 ELECTION RESULTS



All eligible to vote Principal Investigators (520) from EBMT full membership centres were invited to vote online for the nominated, endorsed and approved candidates for 2021.

Voting took place online from Tuesday 2nd March until Monday 15th March, 2021

267 votes were submitted from 520 eligible voters = 51% participation.


EBMT President Elect PLURALITY

Anna Sureda	141 votes (53.0%)
Christian Chabannon	31 votes (11.7%)
Ibrahim Yakoub-Agha	94 votes (35.3%)


Anna Sureda wins with 53.0% of the vote.

266 votes tallied and 1 abstention from 267 ballots

■ ■ ■ Anna Sureda ■ ■ ■ Christian Chabannon ■ ■ ■ Ibrahim Yakoub-Agha



Congratulations to Anna Sureda, EBMT President Elect.



EBMT Transplant Complications Working Party Chair PLURALITY

Zinaida Perić

136 votes (55.1%)

Olaf Penack

111 votes (44.9%)

Zinaida Perić wins with 55.1% of the vote.

247 votes tallied and 20 abstentions from 267 ballots

||||| Zinaida Perić ■■■■ Olaf Penack



Congratulations to **Zinaida Peric**, EBMT Transplant Complications Working Party Chair.



EBMT Inborn Errors Working Party Chair PLURALITY

Bénédicte Neven

115 votes (54.2%)


Michael Albert

97 votes (45.8%)

Bénédicte Neven wins with 54.2% of the vote.

212 votes tallied and 55 abstentions from 267 ballots

■■■■ Bénédicte Neven ■■■■ Michael Albert



Congratulations to **Bénédicte Neven**, EBMT Inborn Errors Working Party Chair.



2020 ANNUAL REPORTS APPROVAL



In addition to voting for the 2021 candidates, all eligible to vote PIs, were also invited to approve the EBMT annual reports for 2020 in advance of the annual general assembly meeting.

EBMT President's Activity Report
EBMT Secretary's Membership Report
EBMT Treasurer's Financial Report

EBMT President's Annual Report for 2020 PLURALITY

Yes - I approve the President's Annual Report for 2020

251 votes (98.8%)

No - I reject the President's Annual Report for 2020


3 votes (1.2%)

Yes - I approve the President's Annual Report for 2020 wins with 98.8% of the vote.

254 votes tallied and 13 abstentions from 267 ballots

Yes - I approve the President's Annual Report for 2020

No - I reject the President's Annual Report for 2020



EBMT Treasurer's Annual Report for 2020 PLURALITY

Yes - I approve the Treasurer's Annual Report for 2020

240 votes (99.2%)

No - I reject the Treasurer's Annual Report for 2020


2 votes (0.8%)

Yes - I approve the Treasurer's Annual Report for 2020 wins with 99.2% of the vote.

242 votes tallied and 25 abstentions from 267 ballots

Yes - I approve the Treasurer's Annual Report for 2020

No - I reject the Treasurer's Annual Report for 2020





EBMT Secretary's Annual Report for 2020 PLURALITY

Yes - I approve the Secretary's Annual Report for 2020	247 votes (99.6%)
No - I reject the Secretary's Annual Report for 2020	1 vote (0.4%)

Yes - I approve the Secretary's Annual Report for 2020 wins with 99.6% of the vote.

248 votes tallied and 19 abstentions from 267 ballots



Thank you



OUTGOING BOARD MEMBERS 2021

We would like to take this opportunity to thank the following outgoing board members for their support and commitment to the Scientific Council and Board of Association during their 2017-2021 mandates.





Arjan Lankester

EBMT Inborn Errors Working Party Chair and member of the EBMT
Scientific Council from 2017-2021



Grzegorz Basak

EBMT Transplant Complications Working Party Chair, member of the
EBMT Scientific Council (2017-2021) and Board of Association with education
portfolio (2018-2020)



John Murray
EBMT Nurses Group President, member of the EBMT Scientific Council and
Board of Association from 2017-2021

OUTGOING BOARD MEMBERS 2020


We would like to take this opportunity to thank the following outgoing board members for their support and commitment to the Scientific Council and Board of Association during their 2016-2020 mandates.





Rafael Duarte

EBMT Secretary, member of the EBMT Executive Committee and Board of Association from 2016-2020



Silvia Montoto

EBMT Lymphoma Working Party Chair and member of the EBMT Scientific Council from 2016-2020



John Snowden

EBMT Autoimmune Diseases Working Party Chair, member of the EBMT Scientific Council (2016-2020) and Board of Association with Registry portfolio (2018-2020)



Jan Styczynski

EBMT Infectious Diseases Working Party Chair and member of the EBMT
Scientific Council from 2016-2020

Thank you!

